ArticleNPJ digital medicine2026
DARE-FUSE: domain aligned evidence guided learning for joint brain tumor MRI segmentation and classification.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Brain tumor MRI segmentation and classification are essential for preoperative boundary assessment, lesion burden quantification, postoperative response monitoring, and radiotherapy planning, yet edema overlap, sequence heterogeneity, and artifacts often blur lesion margins. Together with the high cost of pixel-level annotation, these factors limit robust, cross-institution deployment. We propose DARE-FUSE (Domain Aligned Representation with Evidence-guided FUSE), a unified framework for pixel-level segmentation and image-level classification under limited samples and labels. Dual encoders with a feature-interaction bridge learn a shared embedding, and a Domain Alignment Refiner maps it to task-aligned representations for the segmentation and classification branches. For segmentation, U-SEG decodes features and SEGU outputs pixel-wise uncertainty to regularize boundary over/under-segmentation. For classification, CPG produces predictions and multi-scale Grad-CAM++ evidence. A Generative Lesion Removal Prior reconstructs a tumor-free counterpart to yield a difference prior, and FUSE combines this prior with Grad-CAM++ under uncertainty attenuation to guide segmentation and suppress hallucinations. DARE-FUSE achieves stable, leading performance on BraTS segmentation benchmarks and several classification datasets; ablations and label-reduction experiments confirm complementary gains and smooth degradation as pixel annotations decrease. The resulting uncertainty maps and continuous priors support interpretable decision assistance in surgery, radiotherapy contouring, triage, and longitudinal follow-up.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.